Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Tukhvatulin AI, Dolzhikova IV, Dzharullaeva AS, Grousova DM, Kovyrshina AV, Zubkova OV, Zorkov ID, Iliukhina AA, Shelkov AY, Erokhova AS, Popova O, Ozharovskaia TA, Zrelkin DI, Izhaeva FM, Shcheblyakov DV, Esmagambetov IB, Tokarskaya EA, Nikitenko NA, Lubenets NL, Khadorich EA, Gushchin VA, Borzakova SN, Vlasova AV, Osmanov IM, Gorev VV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: dzharullaeva as. Front Immunol. 2023 Aug 1;14:1228461. doi: 10.3389/fimmu.2023.1228461. eCollection 2023. Front Immunol. 2023. PMID: 37600800 Free PMC article. Clinical Trial.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Logunov DY, et al. Among authors: dzharullaeva as. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Lancet. 2020. PMID: 32896291 Free PMC article. Clinical Trial.
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Logunov DY, et al. Among authors: dzharullaeva as. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Lancet. 2021. PMID: 33545094 Free PMC article. Clinical Trial.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine "Sputnik Light" for prevention of coronavirus infection in healthy adults.
Tukhvatulin AI, Dolzhikova IV, Shcheblyakov DV, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaia TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zubkova TG, Zakharov KA, Vasilyuk VB, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: dzharullaeva as. Lancet Reg Health Eur. 2021 Dec;11:100241. doi: 10.1016/j.lanepe.2021.100241. Epub 2021 Nov 2. Lancet Reg Health Eur. 2021. PMID: 34746910 Free PMC article.
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
Tukhvatulin AI, Gordeychuk IV, Dolzhikova IV, Dzharullaeva AS, Krasina ME, Bayurova EO, Grousova DM, Kovyrshina AV, Kondrashova AS, Avdoshina DV, Gulyaev SA, Gulyaeva TV, Moroz AV, Illarionova VV, Zorkov ID, Iliukhina AA, Shelkov AY, Botikov AG, Erokhova AS, Shcheblyakov DV, Esmagambetov IB, Zubkova OV, Tokarskaya EA, Savina DM, Vereveyko YR, Ungur AS, Naroditsky BS, Ishmukhametov AA, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: dzharullaeva as. Emerg Microbes Infect. 2022 Dec;11(1):2229-2247. doi: 10.1080/22221751.2022.2119169. Emerg Microbes Infect. 2022. PMID: 36031930 Free PMC article.
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.
Panova EA, Kleymenov DA, Shcheblyakov DV, Bykonia EN, Mazunina EP, Dzharullaeva AS, Zolotar AN, Derkaev AA, Esmagambetov IB, Sorokin II, Usachev EV, Noskov AN, Ivanov IA, Zatsepin TS, Dmitriev SE, Gushchin VA, Naroditsky BS, Logunov DY, Gintsburg AL. Panova EA, et al. Among authors: dzharullaeva as. Front Immunol. 2023 Feb 14;14:1098302. doi: 10.3389/fimmu.2023.1098302. eCollection 2023. Front Immunol. 2023. PMID: 36865543 Free PMC article.
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Dzharullaeva AS, Tukhvatulina NM, Shcheblyakov DV, Shmarov MM, Tokarskaya EA, Simakova YV, Egorova DA, Scherbinin DN, Tutykhina IL, Lysenko AA, Kostarnoy AV, Gancheva PG, Ozharovskaya TA, Belugin BV, Kolobukhina LV, Pantyukhov VB, Syromyatnikova SI, Shatokhina IV, Sizikova TV, Rumyantseva IG, Andrus AF, Boyarskaya NV, Voytyuk AN, Babira VF, Volchikhina SV, Kutaev DA, Bel'skih AN, Zhdanov KV, Zakharenko SM, Borisevich SV, Logunov DY, Naroditsky BS, Gintsburg AL. Dolzhikova IV, et al. Among authors: dzharullaeva as. Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620. doi: 10.1080/21645515.2016.1238535. Epub 2017 Feb 2. Hum Vaccin Immunother. 2017. PMID: 28152326 Free PMC article. Clinical Trial.
Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.
Ozharovskaia TA, Zubkova OV, Dolzhikova IV, Gromova AS, Grousova DM, Tukhvatulin AI, Popova O, Shcheblyakov DV, Scherbinin DN, Dzharullaeva AS, Erokhova AS, Shmarov MM, Loginova SY, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Ozharovskaia TA, et al. Among authors: dzharullaeva as. Acta Naturae. 2019 Jan-Mar;11(1):38-47. Acta Naturae. 2019. PMID: 31024747 Free PMC article.
Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice.
Tukhvatulin A, Dzharullaeva A, Erokhova A, Zemskaya A, Balyasin M, Ozharovskaia T, Zubkova O, Shevlyagina N, Zhukhovitsky V, Fedyakina I, Pruss I, Shcheblyakov D, Naroditsky B, Logunov D, Gintsburg A. Tukhvatulin A, et al. Vaccines (Basel). 2020 Sep 10;8(3):519. doi: 10.3390/vaccines8030519. Vaccines (Basel). 2020. PMID: 32927915 Free PMC article.
21 results